Last 12 months
Inside the activity.
0 purchase rows · 9 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2020 Filed Jan 7, 2020 00:06 UTC |
FORMELA JEAN FRANCOISDirector
|
GrantStock Option (right to buy) · Derivative | 5,408 | $6.47 Strike: $9.87 | $34,989.76 |
DisclosureSEC source: 0000899243-20-000629 · doc4.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,408 Underlying: Common Stock · 5,408 shares Expires 2030-01-02 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $35,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. The proceeds of any sales of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Advisors, LLC and as such, the Reporting Person disclaims his beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 00:09 UTC |
THOMAS FRANK EDirector
|
GrantStock Option (right to buy) · Derivative | 2,704 | $6.47 Strike: $9.87 | $17,494.88 |
DisclosureSEC source: 0000899243-20-000631 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,704 Underlying: Common Stock · 2,704 shares Expires 2030-01-02 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $17,500 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 00:05 UTC |
VINK PATRICK V.J.J.Director
|
GrantStock Option (right to buy) · Derivative | 5,408 | $6.47 Strike: $9.87 | $34,989.76 |
DisclosureSEC source: 0000899243-20-000628 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,408 Underlying: Common Stock · 5,408 shares Expires 2030-01-02 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $35,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 00:03 UTC |
Deshpande MilindDirector
|
GrantStock Option (right to buy) · Derivative | 5,408 | $6.47 Strike: $9.87 | $34,989.76 |
DisclosureSEC source: 0000899243-20-000625 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,408 Underlying: Common Stock · 5,408 shares Expires 2030-01-02 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $35,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:48 UTC |
FORMELA JEAN FRANCOISDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015667 · doc4.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership to the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:54 UTC |
Smith CynthiaDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015673 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:53 UTC |
Pottage John C JrDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015672 · doc4.xml · derivative · entry 1 Pottage John C Jr · CIK 0001378587 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:50 UTC |
THOMAS FRANK EDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015668 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:47 UTC |
Deshpande MilindDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015665 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:45 UTC |
VINK PATRICK V.J.J.Director
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015663 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 23:29 UTC |
Smith CynthiaDirector
|
GrantStock Option (right to buy) · Derivative | 12,146 | $0.00 Strike: $12.81 | $0.00 |
DisclosureSEC source: 0000899243-19-009318 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,146 Underlying: Common Stock · 12,146 shares Expires 2029-03-29 F1 · derivative.exercise_date: The shares underlying this option will vest in thirty-six equal monthly installments at the end of each successive month following March 29, 2019, subject to the Reporting Person's continued service as a director through the applicable vesting dates. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:23 UTC |
Parr Thomas R JRChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0000899243-19-000183 · doc4.xml · derivative · entry 1 Parr Thomas R JR · CIK 0001413008 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:20 UTC |
Melnick David A.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0000899243-19-000181 · doc4.xml · derivative · entry 1 Melnick David A. · CIK 0001726485 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:18 UTC |
Larkin CristinaChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0000899243-19-000179 · doc4.xml · derivative · entry 1 Larkin Cristina · CIK 0001721173 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:16 UTC |
Sendek JoelChief Financial Officer
|
GrantStock Option (Right to Buy · Derivative | 65,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0000899243-19-000178 · doc4.xml · derivative · entry 1 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:12 UTC |
Mahadevia AnkitDirector · CEO and President
|
GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0000899243-19-000175 · doc4.xml · derivative · entry 1 Mahadevia Ankit · CIK 0001720974 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 21, 2018 Filed Sep 21, 2018 21:38 UTC |
Pottage John C JrDirector
|
GrantStock Option (right to buy) · Derivative | 12,146 | $0.00 Strike: $10.25 | $0.00 |
DisclosureSEC source: 0000899243-18-025024 · doc4.xml · derivative · entry 1 Pottage John C Jr · CIK 0001378587 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,146 Underlying: Common Stock · 12,146 shares Expires 2028-09-21 F1 · derivative.exercise_date: The shares underlying this option will vest in thirty-six equal monthly installments at the end of each successive month following September 21, 2018, subject to the Reporting Person's continued service as a director through the applicable vesting dates. Read SEC document |
| July 17, 2018 Filed Jul 17, 2018 21:01 UTC |
GSK plc10% owner
|
PurchaseCommon Stock | 80,000 | $12.50 | $1,000,000.00 |
DisclosureSEC source: 0000903423-18-000400 · glaxo-spero.xml · nonDerivative · entry 1 GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By S.R. One, Limited Disclosed balance after: 1,934,006 F1 · ownership.nature: S.R. One, Limited acquired 80,000 common shares of the Issuer in connection with the Issuer's offering. Shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (Reporting Person). Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · derivative · entry 12 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,888 Underlying: Common Stock · 1,600 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option were fully vested as of July 6, 2017. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
SaleCommon Stock | 200 | $17.92 | $3,584.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 10 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,817 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
SaleCommon Stock | 200 | $17.90 | $3,580.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 9 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,017 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
SaleCommon Stock | 100 | $17.71 | $1,770.50 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 8 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,217 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
SaleCommon Stock | 100 | $17.62 | $1,762.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 7 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,317 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
SaleCommon Stock | 400 | $17.58 | $7,032.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 6 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,417 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
SaleCommon Stock | 100 | $17.55 | $1,754.50 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 5 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,817 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
SaleCommon Stock | 500 | $17.50 | $8,750.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 4 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,917 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
Exercise / conversionCommon Stock | 1,600 | $5.90 | $9,440.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 3 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:45 UTC |
Larkin CristinaChief Operating Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-18-019568 · doc4.xml · derivative · entry 3 Larkin Cristina · CIK 0001721173 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,434 Underlying: Common Stock · 4,000 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vested as to 25% on March 7, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:45 UTC |
Larkin CristinaChief Operating Officer
|
SaleCommon Stock | 4,000 | $17.50 | $70,000.00 |
DisclosureSEC source: 0000899243-18-019568 · doc4.xml · nonDerivative · entry 2 Larkin Cristina · CIK 0001721173 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · kind: The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:45 UTC |
Larkin CristinaChief Operating Officer
|
Exercise / conversionCommon Stock | 4,000 | $5.90 | $23,600.00 |
DisclosureSEC source: 0000899243-18-019568 · doc4.xml · nonDerivative · entry 1 Larkin Cristina · CIK 0001721173 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:44 UTC |
Sendek JoelChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-18-019567 · doc4.xml · derivative · entry 3 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,833 Underlying: Common Stock · 2,000 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested as to 25% on May 1, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:44 UTC |
Sendek JoelChief Financial Officer
|
SaleCommon Stock | 2,000 | $17.50 | $35,000.00 |
DisclosureSEC source: 0000899243-18-019567 · doc4.xml · nonDerivative · entry 2 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,181 F1 · kind: The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 10,181 shares of common stock held by the Joel D. Sendek Retained Annuity Trust No. 1, of which the Reporting Person is a trustee. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:44 UTC |
Sendek JoelChief Financial Officer
|
Exercise / conversionCommon Stock | 2,000 | $5.90 | $11,800.00 |
DisclosureSEC source: 0000899243-18-019567 · doc4.xml · nonDerivative · entry 1 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 10,181 shares of common stock held by the Joel D. Sendek Retained Annuity Trust No. 1, of which the Reporting Person is a trustee. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,076 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · derivative · entry 11 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,488 Underlying: Common Stock · 3,076 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option were fully vested as of July 6, 2017. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
SaleCommon Stock | 3,076 | $17.62 | $54,203.73 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 2 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,817 F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 01:41 UTC |
Mahadevia AnkitDirector · See Remarks
|
Exercise / conversionCommon Stock | 3,076 | $5.90 | $18,148.40 |
DisclosureSEC source: 0000899243-18-019566 · doc4.xml · nonDerivative · entry 1 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017. F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 00:01 UTC |
FORMELA JEAN FRANCOISDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015329 · doc4.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 00:02 UTC |
THOMAS FRANK EDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015330 · doc4.xml · derivative · entry 1 THOMAS FRANK E · CIK 0001242616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 00:01 UTC |
SOUTHWELL DAVID PDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015328 · doc4.xml · derivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 00:00 UTC |
Deshpande MilindDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015326 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 00:01 UTC |
Breum CasperDirector
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015327 · doc4.xml · derivative · entry 1 Breum Casper · CIK 0001630850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 00:00 UTC |
VINK PATRICK V.J.J.Director
|
GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015325 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| March 30, 2018 Filed Mar 30, 2018 21:30 UTC |
SOUTHWELL DAVID PDirector
|
GrantStock Option (right to buy) · Derivative | 12,146 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0000899243-18-008989 · doc4.xml · derivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,146 Underlying: Common Stock · 12,146 shares Expires 2028-03-30 F1 · derivative.exercise_date: The shares underlying this option will vest in thirty-six equal monthly installments at the end of each successive month following March 30, 2018, subject to the Reporting Person's continued service as a director through the applicable vesting dates. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 15:11 UTC |
Melnick David A.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0000899243-18-000561 · doc4.xml · derivative · entry 1 Melnick David A. · CIK 0001726485 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 4, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:07 UTC |
Larkin CristinaChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 62,540 | $0.00 Strike: $11.63 | $0.00 |
DisclosureSEC source: 0000899243-17-028851 · doc4.xml · derivative · entry 1 Larkin Cristina · CIK 0001721173 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,540 Underlying: Common Stock · 62,540 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:06 UTC |
Sendek JoelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 27,795 | $0.00 Strike: $11.63 | $0.00 |
DisclosureSEC source: 0000899243-17-028850 · doc4.xml · derivative · entry 1 Sendek Joel · CIK 0001720875 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,795 Underlying: Common Stock · 27,795 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:05 UTC |
Parr Thomas R JRChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 36,134 | $0.00 Strike: $11.63 | $0.00 |
DisclosureSEC source: 0000899243-17-028848 · doc4.xml · derivative · entry 1 Parr Thomas R JR · CIK 0001413008 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,134 Underlying: Common Stock · 36,134 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:05 UTC |
Mahadevia AnkitDirector · See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 125,079 | $0.00 Strike: $11.63 | $0.00 |
DisclosureSEC source: 0000899243-17-028846 · doc4.xml · derivative · entry 1 Mahadevia Ankit · CIK 0001720974 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,079 Underlying: Common Stock · 125,079 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:08 UTC |
FORMELA JEAN FRANCOISDirector
|
ConversionSeries C Preferred Stock · Derivative | 3,662,178 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-025510 · doc4.xml · derivative · entry 11 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 602,589 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). Each series of preferred stock was automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date. F2 · derivative.exercise_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). Each series of preferred stock was automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date. F2 · derivative.expiration_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). Each series of preferred stock was automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date. F4 · ownership.nature: Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Formela is a member of AVA X LLC and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:08 UTC |
FORMELA JEAN FRANCOISDirector
|
ConversionSeries C Preferred Stock · Derivative | 3,119,633 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-025510 · doc4.xml · derivative · entry 10 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 513,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). Each series of preferred stock was automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date. F2 · derivative.exercise_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). Each series of preferred stock was automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date. F2 · derivative.expiration_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). Each series of preferred stock was automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date. F3 · ownership.nature: Shares held by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.